NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and Autonomous Therapeutics, Inc. (Autonomous), a leader developing first-in-class, diseaseactivated RNA medicines, announced a research collaboration aimed at effectively targeting and treating metastatic tumors. This collaboration will leverage Autonomous' precision encrypted RNA™ (encRNA) techno ...